Welcome Guest
Home » Reports » Biotherapeutics: Novel Formulation and Delivery Approaches (Focus on Antibodies and Proteins)

Biotherapeutics: Novel Formulation and Delivery Approaches (Focus on Antibodies and Proteins)

Published: Nov 10, 2015
Pages: 301
Product Code: RA10049
License Type :  (Learn More)

Biopharmaceuticals is currently one of the fastest growing segments in the pharmaceutical industry. They have a vital use in the treatment of chronic diseases and also result in high profit margins for the drug developers. There are several therapeutic areas for which biopharmaceuticals are being investigated; these include oncology, metabolic disorders, viral infections, genetic disorders and immunological disorders. Biotherapeutics (both approved and under investigation) include monoclonal antibodies, cell therapies, clotting factors, cytokines, enzymes, hormones and vaccines. In fact, several antibody based therapies have already been approved across the globe. Humira®, by AbbVie, is a well-known example; the drug has been generating multibillion dollar sales annually for several years.

 

The major challenge for biologics has been the mode of administration. For most large molecule drugs, IV is an established route. Through this method, the drug directly enters systemic circulation bypassing degradation in the gastrointestinal (GI) tract. However, there are other challenges; these include the requirement of healthcare experts for drug administration (in turn, increasing the cost of therapy) and associated pain during therapy administration (negatively impacting patient compliance).Companies developing biologics are continuously on the lookout for novel formulation and delivery systems in order to exploit their full therapeutic and commercial potential. Amongst the various aspects being studied, technologies for facilitating oral, subcutaneous (SC) and transdermal delivery of biologics are highly sought after and have received widespread attention from researchers and manufacturers across the globe.

 

Several start-ups, with innovative technologies, have surfaced in the past decade and have continuously encouraged the use of biotherapeutics by providing novel approaches to improve patient compliance. These technologies are broadly classified either as formulation technologies (approaches with primary objective of changing the formulation of drug, thereby facilitating an alternate route of administration in many cases) or delivery systems (approaches with primary objective of developing a physical system to deliver the drug via an alternate route).

 

The overall interest continues to rise as is evident from the number of partnerships / agreements that have taken place amongst the stakeholders. Technology licensing agreements have been very common and are likely to play an active role in industry’s development. In addition, several venture capitalists have led multiple funding rounds in these companies, acting as a key enabler behind the evolution.

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The ‘Biotherapeutics: Novel Formulation and Delivery Approaches (Focus on Antibodies and Proteins)’ report provides a comprehensive analysis of the current market landscape and the future outlook of technologies focused on the formulation and delivery of biotherapeutics, primarily proteins and antibodies. Biopharmaceuticals has become an area of heavy interest for many pharmaceutical companies; they make up about one-third of all the drugs that are currently in development. The industry is growing at a healthy pace resulting in a substantial shift from conventional chemical synthesis to biotechnological processes in the way drugs are now produced.

 

Intravenous (IV) route has been the most popular route for administering large molecule drugs such as proteins and antibodies. However, with the rising popularity of biologics and biosimilars, several companies are now looking forward to technologies that can be used for delivering biotherapeutics via a route other than IV injection or infusion. Technologies focused on oral, SC and transdermal routes are becoming more popular and, therefore, are expected to be the major contributors to the overall drug delivery technologies market. In addition, there are other novel targeted approaches, such as bypassing blood brain barrier, which are likely to change the industry paradigm in the long run.

 

During the course of our research, we identified 122 such companies that are developing either formulation technologies or novel systems for delivery of large molecule drugs. The study not only provides the list of technologies but also includes a detailed analysis on the overall market for these technologies. We have looked at the investments that have been made into these technologies and have provided detailed information of the various collaborations / licensing agreements amongst the stakeholders. This advancing trend of transition from IV to alternate delivery mechanisms highlights the crucial role of technology developers in this field.

 

The base year for the report is 2015. The report provides the market forecast for the period 2015-2025. The research, analysis and insights presented in this report are backed by a deep understanding,developed from both primary and secondary research, of key drivers behind the growth.

 

 

Example Highlights

  1. There are over 150 technologies, being developed by around 120 companies, which are focused on developing novel formulations and / or systems for delivering antibodies and proteins. Amongst the delivery systems, prime focus of the stakeholders is on oral, SC and transdermal drug delivery technologies.
  2. The market has attracted several start-ups; these companies, in collaboration with big pharma, are expected to foster more innovation in the near future. Some of the well-known players with proprietary technologies are (in alphabetical order) Adocia, Aegis Therapeutics, Arecor, Corium International, Cosmo Pharmaceuticals, Durect Corporation, Emisphere Technologies, Excelse Bio, Generex Biotechnology, Halozyme Therapeutics, Merrion Pharmaceuticals, Oramed Pharmaceuticals, Rani Therapeutics, Xeris Pharmaceuticals and Zosano Pharma (complete list in Chapter 4 of the report).
  3. These approaches focus on a wide range of mechanisms; amongst others, these include modifying the release properties along with pharmacokinetic properties, creating cold-chain free and stable liquid formulations of the drug and delivering the drugs in a targeted manner.
  4. Within the technologies focused on targeted delivery, there seems to be heavy focus on delivery of drugs across the Blood Brain Barrier (BBB). Delivery across the BBB has been a big challenge in case of large sized biologics. We have identified over 15 players, which aim to successfully overcome this challenge in the coming few years.
  5. Venture capitalists have shown an enormous amount of interest and confidence in the technology developers. In total, we traced over 200 instances of funding with the total investment amounting to an encouraging sum of USD 2.9 billion over the last decade. In addition, government agencies, such as the NIH, have also encouraged technology developers by issuing grants for a wide range of research projects.
  6. Driven by several factors, such as rising incidence of chronic diseases, growing popularity of biologics / biosimilars and use of delivery / formulation technologies as life cycle management tools for near patent expiry drugs, the market for such technologies is expected to grow aggressively at a healthy annual growth rate of 9.6% between 2015 and 2025.

 

 

Research Methodology

Most of the data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

 

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our study. The summary offers a high level view on the likely market evolution of the drug delivery technologies for biotherapeutics.

 

Chapter 3 is an introductory chapter on biotherapeutics. It includes the various advantages and challenges faced by technology developers in developing systems for delivering biotherapeutics. We have also presented, in detail, a discussion on the approved antibody therapeutics in the market, signifying the growing trend towards alternate delivery mechanisms.

 

Chapter 4 identifies the various approaches / technologies / systems that can be used to formulate and administer biologics. The classification system for the technologies mentioned in this chapter helps develop a deeper understanding of the market.

 

Chapter 5 reviewsthe key technologies available for oral delivery of biotherapeutics. We have presented profiles of several leading technologies covering information on their origin, mechanism, molecules based on these technologies and associated companies.

 

Chapter 6 includes profiles of key technology developers specialising in formulating and delivering biotherapeutics via the SC route. Each profile includes information such as technology overview, pipeline review, funding details and recent developments.

 

Chapter 7reviews the major technologies available for transdermal/intradermal administration of biotherapeutics. Several leading companies, along with their technologies, have been profiled in this chapter. As in earlier chapters, these profiles provide an overview of the technology developers, mechanism of technologies, drugs in the pipeline based on specific technologies and associated recent developments.

 

Chapter 8 discusses technologies focused on other alternative administration routes (other than oral, SC and transdermal). The chapter includes key insights on technologies that alter the release kinetics and pharmacokinetics of the drug. In addition, certain technologies focused on targeted delivery, such as delivery across the blood-brain-barrier, have also been covered in this chapter.

 

Chapter 9 highlights the recent partnerships that have taken place in the industry. We have also discussed the various partnership models in existence and the most common forms of deals/agreements that have evolved over time.

 

Chapter 10provides information on several funding instances that have driven research and development of formulation and delivery technologies for biotherapeutics. Our analysis reveals interesting insights on the growing interest of venture capitalists and other stakeholders in this market.

 

Chapter 11 presents a detailed ten year forecast highlighting the potential for technology developers engaged in developing technologies for delivery of biotherapeutics. Due to the uncertainty surrounding some of the key assumptions, we have presented three different growth tracks outlined as the conservative, base and optimistic scenarios. Our insights are backed by discussions with several stakeholders in the industry.

 

Chapter 12 provides a SWOT analysis of the drug delivery technologies market for biotherapeutics, giving strategic insights to the major factors that are likely to drive future growth whilst highlighting the weaknesses and threats that may negatively impact the industry’s evolution.

 

Chapter 13 is a collection of transcripts of interviews conducted with key players during the course of this study.

 

Chapter 14 summarises the overall report. In this chapter, we provide a recap of the key takeaways and an independent future outlook based on the research and analysis described in earlier chapters.

 

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

 

Chapter 16 is an appendix, which provides a list of companies and organisations mentioned in the report.

 

 
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. BIOPHARMACEUTICALS: AN INTRODUCTION
3.1. Background and Overview
3.2. Why Biopharmaceuticals are Gaining Attention?
3.3. Different Classes of Biotherapeutics
 
3.4. Biotherapeutics That Can Benefit From Drug Delivery Advances
3.4.1. Monoclonal Antibodies
3.4.2. Cell Therapies
3.4.3. Clotting Factors
3.4.4. Cytokines
3.4.5. Enzymes
3.4.6. Hormones
3.4.7. Vaccines
 
3.5. Antibody Therapies
3.5.1. Landscape of Approved Antibody Therapies
3.5.2. Approved Antibody Therapies: Distribution by Year of Approval
3.5.3. IV Infusion is the Most Common Route of Administration 
3.5.4. Complexities and Complications Associated with the IV Route
 
3.6. Types of Drug Delivery Technologies
3.7. Demand for Novel Drug Delivery Technologies
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Delivery Technologies for Biotherapeutics (Proteins and Antibodies)
4.3. Most of the Technologies Focus on Novel Formulations
4.4. Major Proportion of the Technologies Focus on Specific Route of Administration
 
5. KEY ORAL FORMULATIONAND DELIVERY PLATFORMS
5.1. Chapter Overview
5.2. Technology Licensing is the Most Popular Partnership Model
 
5.3. Gastrointestinal Permeation Enhancement Technology (GIPET®, Merrion Pharmaceuticals)
5.3.1. Overview
5.3.2. Financial Information
5.3.3. Patents
5.3.5. Technology and Mechanism of Action
5.3.6. Advantages of the Technology
5.3.7. Pipeline Drugs Using GIPET®
5.3.8. Agreements / Collaborations
 
5.4. Protein Oral Delivery Technology (POD™, Oramed)
5.4.1. Overview
5.4.2. Financial Information
5.4.3. Patents
5.4.4. Technology and Mechanism of Action
5.4.5. Advantages of the Technology
5.4.6. Pipeline Drugs Using POD™
5.4.7. Agreements / Collaborations
 
5.5. Multi Matrix System (MMX®, Cosmo Pharmaceuticals)
5.5.1. Overview
5.5.2. Financial Information
5.5.3. Patents
5.5.4. Technology and Mechanism of Action
5.5.5. Advantages of the Technology
5.5.6. Pipeline Drugs Using MMX® Technology
5.5.7. Agreements / Collaborations
 
5.6. Eligen® (Emisphere Technologies)
5.6.1. Overview
5.6.2. Financial Information
5.6.3. In-house Development of Eligen
5.6.4. Technology and Mechanism of Action
5.6.5. Advantages of the Technology
5.6.6. Pipeline Drugs Using Eligen®
5.6.7. Agreements / Collaborations
 
5.7. RapidMist™ (Generex Biotechnology™)
5.7.1. Overview
5.7.2. Financial Performance
5.7.3. Technology and Mechanism of Action
5.7.4. Advantages of the Technology
5.7.5. Pipeline Drugs Using RapidMist™
5.7.6. Agreements / Collaborations
 
5.8. Axcess™ (Proxima Concepts)
5.8.1. Overview
5.8.2. Patents
5.8.3. Technology and Mechanism of Action
5.8.4. Advantages of the Technology
5.8.5. Pipeline Drugs Using Axcess™
5.8.6. Agreements / Collaborations
 
6. KEY SUBCUTANEOUS FORMULATION AND DELIVERY PLATFORMS
6.1. Chapter Overview
6.2. Technology Licensing and Research Collaboration are the Two Popular Partnership Models
 
6.3. ENHANZE™ Technology (Halozyme Therapeutics)
6.3.1. Overview
6.3.2. Financial Performance
6.3.3. Technology and Mechanism of Action
6.3.4. Advantages of the Technology
6.3.5. Pipeline Drugs Using ENHANZE™
6.3.6. Agreements / Collaborations
 
6.4. Bepo™ (MedinCell)
6.4.1. Overview
6.4.2. Patents
6.4.3. Technology and Mechanism of Action
6.4.4. Advantages of the Technology
6.4.5. Pipeline Drugs Using BEPO™
6.4.6. Agreements / Collaborations
 
6.5. Medusa™ (Flamel Technologies)
6.5.1. Overview
6.5.2. Financial Performance
6.5.3. Technology and Mechanism of Action
6.5.4. Advantages of the Technology
6.5.5. Pipeline Drugs Using Medusa™
6.5.6. Agreements / Collaborations
 
6.6. XeriJect™ (Xeris Pharmaceuticals)
6.6.1. Overview
6.6.2. Financial Information
6.6.3. Technology and Mechanism of Action
6.6.4. Advantages of the Technology
6.6.5. Pipeline Drugs Using XeriJect™
6.6.6. Agreements / Collaborations
 
6.7. BioChaperone® (Adocia)
6.7.1. Overview
6.7.2. Financial Performance
6.7.3. Technology and Mechanism of Action
6.7.4. Advantages of the Technology
6.7.5. Pipeline Drugs Using BioChaperone®
6.7.6. Agreements / Collaborations
 
6.8. Crystalomics® Technology (Ajinomoto Althea)
6.8.1. Overview
6.8.2. Financial Performance
6.8.3. Technology and Mechanism of Action
6.8.4. Advantages of the Technology
6.8.5. Pipeline Drugs Using Crystalomics®
6.8.6. Agreements / Collaborations
 
6.9. TransCon Technology (Ascendis Pharma)
6.9.1. Overview
6.9.2. Financial Information
6.9.3. Technology and Mechanism of Action
6.9.4. Advantages of the Technology
6.9.5. Pipeline Drugs Using TransCon
6.9.6. Agreements / Collaborations
 
7. KEY DERMAL FORMULATION AND DELIVERY PLATFORMS
7.1. Chapter Overview
7.2. Technology Licensing is the Most Common Agreement Model
 
7.3. MicroCor® Technology (Corium International)
7.3.1. Overview
7.3.2. Financial Performance
7.3.3. Patents
7.3.4. Technology and Mechanism of Action
7.3.5. Pipeline Drugs Using MicroCor®
7.3.6. Agreements / Collaborations
 
7.4. MicronJet (NanoPass Technologies)
7.4.1. Overview
7.4.2. Financial Information
7.4.3. Technology and Mechanism of Action
7.4.4. Pipeline Drugs Using MicronJet Needle
7.4.5. Agreements / Collaborations
 
7.5. ZP Patch Technology (Zosano Pharma™)
7.5.1. Overview
7.5.2. Financial Performance
7.5.3. Technology and Mechanism of Action
7.5.4. Pipeline Drugs Using ZP Patch
7.5.5. Agreements / Collaborations
 
8. OTHER FORMULATION AND DELIVERY PLATFORMS
8.1. Chapter Overview
8.2. Product Development and Evaluation Agreement are Preferred Modes of Collaboration
 
8.3. nanoZYME™, poloMAC™ and poxoMAC™ (NeuroNano Pharma)
8.3.1. Overview
8.3.2. nanoZYME™ Technology
8.3.3. poloMAC™ and poxoMAC™ Technologies
8.3.4. NeuroNano Pharma: Patent Portfolio
8.3.5. Agreements / Collaborations
 
8.4. ß-Eliminative Drug Delivery System (ProLynx)
8.4.1. Overview
8.4.2. Technology and Mechanism of Action
8.4.3. Advantages of the Technology
8.4.4. Patent Portfolio
8.4.5. Agreements / Collaborations
 
8.5. Intravail® and Aegis Hydrogels® (Aegis Therapeutics)
8.5.1. Overview
8.5.2. Intravail® Technology
8.5.3. Aegis Hydrogels® Technology
8.5.4. Agreements / Collaborations
 
8.6. PharmFilm® Technology (MonoSol Rx)
8.6.1. Overview
8.6.2. Financial Performance
8.6.3. Technology and Mechanism of Action
8.6.4. Advantages of the Technology
8.6.5. Pipeline Drugs Using PharmFilm® Technology
8.6.6. Agreements / Collaborations
 
8.7. PLEX™ Platform (PolyPid)
8.7.1. Overview
8.7.2. Financial Information
8.7.3. Technology and Mechanism of Action
8.7.4. Advantages of the Technology
8.7.5. Pipeline Drugs Using PLEX™
8.7.6. Agreements / Collaborations
 
8.8. Tethadur (pSivida)
8.8.1. Overview
8.8.2. Financial Performance
8.8.3. Technology and Mechanism of Action
8.8.4. Agreements / Collaborations
 
8.9. Phylomer® Peptides (Phylogica)
8.9.1. Overview
8.9.2. Financial Performance
8.9.3. Technology and Mechanism of Action
8.9.4. Agreements / Collaborations
 
8.11. Transcend Technology (biOasis)
8.11.1. Overview
8.11.2. Financial Performance
8.11.3. Technology and Mechanism of Action
8.11.4. Advantages of the Technology
8.11.5. Pipeline Drugs Using Transcend
8.11.6. Recent Developments
8.11.7. Agreements / Collaborations
 
8.12. LRP Technology (Angiochem)
8.12.1. Overview
8.12.2. Financial Performance
8.12.3. Technology and Mechanism of Action
8.12.4. Pipeline Drugs Using LRP Technology
8.12.5. Agreements / Collaborations
 
9. RECENT PARTNERSHIPS/COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models/Agreements
9.2.1. Product Development and Commercialisation
9.2.2. Technology Licensing 
9.2.3. Research Collaborations
9.2.4. Technology Evaluation
9.2.5. Product Licensing
9.2.6. Manufacturing and Supply
9.2.7. Clinical Trial Collaborations
9.2.8. Other Agreements
 
9.3. Collaborations Amongst the Stakeholders has Steadied
9.4. Product Development and Technology Licensing are Preferred Modes of Partnership
 
10. VENTURE CAPITAL INTEREST
10.1. Chapter Overview
10.2. Instances of Funding for Focused on Formulation and Delivery of Biotherapeutics
10.3. Rising Venture Capital Interest
10.4. Funding Instances: Distribution by Type of Funding
10.5. Leading Technology Developers: Distribution by Number of Funding Instances
10.6. Most Active VC Firms/Institutions
 
11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology
11.3. Overall Drug Delivery Technologies Market, 2015-2025
11.4. Subcutaneous Drug Delivery Technologies Market, 2015-2025
11.5. Oral Drug Delivery Technologies Market, 2015-2025
11.6. Transdermal Drug Delivery Technologies Market, 2015-2025
11.7. Other Drug Delivery Technologies Market, 2015-2025
 
12. SWOT ANALYSIS
12.1. Chapter Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats
 
13. INTERVIEW TRANSCRIPTS
13.1. Interview Transcript I: Dr. Paul Ashton, President and CEO, pSivida
13.2. Interview Transcript II: Tom Saylor, Non-Executive Director, Arecor
13.3. Interview Transcript III: Xavier Rivero, Chief Operating Officer, Sagetis Biotech
13.4. Interview Transcript IV: Rob Hutchison, biOasis, CEO & Chairman
13.5. Interview Transcript V: Quinton Oswald, President and CEO, Neurotech Pharmaceuticals
 
14. CONCLUSION
14.1. Growing Interest Across Several Stakeholders
14.2. Multiple Drivers to Sustain Growth Momentum
14.3. Market for Formulation and Delivery Technologies to Grow at a Healthy Rate
14.4. Emergence of New Technologies
14.5. Concluding Remarks
 
 
Figure 3.1 Classifications of Proteins
 
Figure 3.2 Approved Antibody Therapies: Distribution by Year of Approval
 
Figure 3.3 Approved Antibody Therapies: Distribution by Route of Administration
 
Figure 3.4 Different Types of Drug Delivery Technologies
 
Figure 3.5 Advantages of Novel Drug Delivery Technologies
 
Figure 4.1 Classification of Formulation and Delivery Technologies 
 
Figure 4.2 Formulation and Delivery Technologies: Distribution by Type of Technology
 
Figure 4.3 Formulation and Delivery Technologies: Distribution by Focus of Technology
 
Figure 4.4 Formulation and Delivery Technologies: Distribution by Route of Administration
 
Figure 5.1 Oral Formulation and Drug Delivery Technologies Partnerships: Distribution by Type of Agreement
 
Figure 5.2 Merrion Pharmaceuticals: Revenues, 2012-HY2015 (USD Million)
 
Figure 5.3 Merrion Pharmaceuticals: Funding Instances (USD Million)
 
Figure 5.4 Multifunctional Role of Absorption Enhancer in GIPET®
 
Figure 5.5 Oramed: Funding Instances (USD Million)
 
Figure 5.6 Cosmo Pharmaceuticals: Revenues, 2012-HY2015 (EUR Million)
 
Figure 5.7 MMX® Technology Platform
 
Figure 5.8 Emisphere Technologies: Funding Instances (USD Million)
 
Figure 5.9 Generex Biotechnology™: Funding Instances (USD Million)
 
Figure 6.1 Subcutaneous Formulation and Drug Delivery Technologies: Distribution by Type of Agreement
 
Figure 6.2 Halozyme: Revenues, 2012-HY2015 (USD Million)
 
Figure 6.3 Halozyme Therapeutics: Funding Instances (USD Million)
 
Figure 6.4 BEPO™ Technology: Mechanism
 
Figure 6.5 Flamel Technologies: Revenues, 2012-2014 (USD Million)
 
Figure 6.6 Medusa™ Formulation Technology: Process
 
Figure 6.7 Xeris Pharmaceuticals: Funding Instances (USD Million)
 
Figure 6.8 XeriJect™ Technology: Process
 
Figure 6.9 Adocia: Revenues, 2012-HY2015 (EUR Million)
 
Figure 6.10 Adocia: Funding Instances (USD Million)
 
Figure 6.11 Ascendis Pharma: Funding Instances (USD Million)
 
Figure 7.1 Dermal Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
 
Figure 7.2 Corium: Revenues, 2012-HY2015 (USD Million)
 
Figure 7.3 Zosano Pharma: Revenues, 2013-2014 (USD Million)
 
Figure 7.4 Zosano Pharma:  Funding Instances
 
Figure 8.1 Other Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
 
Figure 8.2 MonoSol Rx: Funding Instances (USD Million)
 
Figure 8.3 PolyPid: Funding Instances (USD Million)
 
Figure 8.4 pSivida: Revenues, 2012-HY2015 (USD Million)
 
Figure 8.5 biOasis: Funding Instances (USD Million)
 
Figure 8.6 Angiochem: Funding Instances (USD Million)
 
Figure 9.1 Product Development/Product Development and Commercialisation Agreements: Distribution by Focus of Technology
 
Figure 9.2 Technology Licensing Agreements: Distribution by Focus of Technology
 
Figure 9.3 Research Collaboration Agreements: Distribution by Focus of Technology
 
Figure 9.4 Technology Evaluation Agreements: Distribution by Focus of Technology
 
Figure 9.5 Product Licensing Agreements: Distribution by Focus of Technology
 
Figure 9.6 Manufacturing and Supply Agreements: Distribution by Focus of Technology
 
Figure 9.7 Clinical Trial Collaborations: Distribution by Focus of Technology
 
Figure 9.8 Other Agreements: Distribution by Focus of Technology
 
Figure 9.9 Delivery in Biotherapeutics: Year Wise Distribution of Partnership Instances
 
Figure 9.10 Collaborations: Most Active Companies
 
Figure 9.11 Collaborations: Distribution by Type of Partnership
 
Figure 10.1 Funding: Cumulative Number of Investments by Year, 1998-2015
 
Figure 10.2 Funding Instances: Distribution by Type of Funding, 1998-2015
 
Figure 10.3 Funding Instances: Distribution by Total Amount Invested, 1998-2015
 
Figure 10.4 Most Active Players: Evaluation by Number of Funding Instances, 1998-2015
 
Figure 10.5 Funding Instances: Distribution by Range of Amount Invested by Type of Funding (USD Million)
 
Figure 10.6 Most Active VC Firms: Evaluation by Number of Funding Instances
 
Figure 11.1 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
 
Figure 11.2 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
 
Figure 11.3 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
 
Figure 11.4 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
 
Figure 11.5 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
 
Figure 11.6 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
 
Figure 11.7 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
 
Figure 11.8 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
 
Figure 11.9 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Base Scenario (USD Billion)
 
Figure 11.10 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
 
Figure 14.1 Overall Biotherapeutics Formulation and Delivery Technologies Market: Comparative Evolution Scenarios, 2015, 2020 and 2025 (USD Billion)
 
 
Table 3.1 Difference between Small Molecule Drugs and Biologics
 
Table 3.2 List of Approved Antibody Therapies
 
Table 4.1 List of Formulation and Delivery Technologies
 
Table 5.1 Merrion Pharmaceuticals: `Patent Portfolio
 
Table 5.2 GIPET® Platforms
 
Table 5.3 GIPET®: Pipeline of Drugs
 
Table 5.4 Merrion Pharmaceuticals: Licensing/Technology Evaluation Agreements
 
Table 5.5 POD™: Patent Portfolio
 
Table 5.6 POD™: Pipeline of Drugs
 
Table 5.7 Oramed: Relevant Agreements / Collaborations
 
Table 5.8 Cosmo Pharmaceuticals: Patent Portfolio
 
Table 5.9 MMX® Technology: Pipeline of Drugs
 
Table 5.10 Cosmo Pharmaceuticals: Relevant Agreements / Collaborations
 
Table 5.11 Eligen®: Pipeline of Drugs
 
Table 5.12 Emisphere Technologies: Relevant Agreements / Collaborations
 
Table 5.13 RapidMist: Pipeline of Drugs
 
Table 5.14 Generex Biotechnology: Technology Licensing/Evaluation Agreements
 
Table 5.15 Axcess Patent Family
 
Table 5.16 Axcess™: Pipeline of Drugs
 
Table 6.1 Enhanze™: Pipeline of Drugs
 
Table 6.2 Halozyme: Technology Licensing/Evaluation Agreements
 
Table 6.3 MedinCell: Patent Portfolio
 
Table 6.4 Medusa™: Pipeline of Drugs
 
Table 6.5 XeriJect™: Pipeline of Drugs
 
Table 6.6 BioChaperone®: Pipeline of Drugs
 
Table 6.7 TransCon: Pipeline of Drugs
 
Table 7.1 MicroCor®: Pipeline of Drugs
 
Table 7.2 MicronJet Needle: Pipeline of Drugs
 
Table 7.3 NanoPass Technologies: Technology Licensing / Evaluation Agreements
 
Table 7.4 Zosano Pharma™: Product Portfolio
 
Table 7.5 Zosano Pharma: Relevant Agreements / Collaborations
 
Table 8.1 NeuroNano Pharma: Patent Portfolio
 
Table 8.2 ProLynx: Patent Portfolio
 
Table 8.3 ProLynx: Technology Licensing/Evaluation Agreements
 
Table 8.4 Aegis Therapeutics: Technology Licensing/Evaluation Agreements
 
Table 8.5 PharmFilm®: Pipeline of Drugs
 
Table 8.6 MonoSol Rx: Technology Licensing Evaluation Agreements
 
Table 8.7 PLEX: Pipeline of Drugs
 
Table 8.8 PolyPid: Relevant Agreements / Collaborations
 
Table 8.9 pSivida: Technology Licensing/Evaluation Agreements
 
Table 8.10 Phylogica: Technology Licensing/Evaluation Agreements
 
Table 8.11 biOasis: Pipeline
 
Table 8.12 biOasis Technologies: Technology Licensing/Evaluation Agreements
 
Table 8.13 LRP Technology: Pipeline of Drugs
 
Table 8.14 Angiochem: Technology Licensing/Evaluation Agreements
 
Table 9.1 Product Development/Product Development and Commercialisation Agreements, 2005 Onwards
 
Table 9.2 Technology Licensing Agreements, 2005 Onwards
 
Table 9.3 Research Collaboration Agreements, 2005 Onwards
 
Table 9.4 Technology Evaluation Agreements, 2005 Onwards
 
Table 9.5 Product Licensing Agreements, 2005 Onwards
 
Table 9.6 Manufacturing and Supply Agreements, 2005 Onwards
 
Table 9.7 Clinical Trial Collaborations, 2005 Onwards
 
Table 9.8 Other Agreements
 
Table 10.1 List of Funding Instances and Investors Involved
 
Table 10.2 Types of Funding Instances, 1998- 2015
 
Table 12.1 SWOT Analysis
 
Table 15.1 Approved Antibody Therapies: Distribution by Year of Approval
 
Table 15.2 Approved Antibody Therapies: Distribution by Route of Administration
 
Table 15.3 Formulation and Delivery Technologies: Distribution by Type of Technology
 
Table 15.4 Formulation and Delivery Technologies: Distribution based on Focus of Technology
 
Table 15.5 Formulation and Delivery Technologies: Distribution by Route of Administration
 
Table 15.6 Oral Formulation and Drug Delivery Technology Partnerships: Distribution by Type of Agreement
 
Table 15.7 Merrion Pharmaceuticals: Revenues, 2012-HY2015 (USD Million)
 
Table 15.8 Merrion Pharmaceuticals: Funding Instances (USD Million)
 
Table 15.9 Oramed: Funding Instances (USD Million)
 
Table 15.10 Cosmo Pharmaceuticals: Revenues, 2012-HY2015 (EUR Million)
 
Table 15.11 Emisphere Technologies: Funding Instances (USD Million)
 
Table 15.12 Generex Biotechnology™: Funding Instances (USD Million)
 
Table 15.13 Subcutaneous Formulation and Drug Delivery Technologies: Distribution by Type of Agreement
 
Table 15.14 Halozyme: Revenues, 2012-HY2015 (USD Million)
 
Table 15.15 Halozyme Therapeutics: Funding Instances (USD Million)
 
Table 15.16 Flamel Technologies: Revenues, 2012-2014 (USD Million)
 
Table 15.17 Xeris Pharmaceuticals: Funding Instances (USD Million)
 
Table 15.18 Adocia: Revenues, 2012-HY2015 (EUR Million)
 
Table 15.19 Adocia: Funding Instances (USD Million)
 
Table 15.20 Ascendis Pharma: Funding Instances (USD Million)
 
Table 15.21 Dermal Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
 
Table 15.22 Corium: Revenues, 2012-HY2015 (USD Million)
 
Table 15.23 Zosano Pharma: Revenues, 2013-2014 (USD Million)
 
Table 15.24 Zosano Pharma:  Funding Instances
 
Table 15.25 Other Formulation and Drug Delivery Technologies: Distribution by Type of Partnership
 
Table 15.26 MonoSol Rx: Funding Instances (USD Million)
 
Table 15.27 PolyPid: Funding Instances (USD Million)
 
Table 15.28 pSivida: Revenues, 2012-HY2015 (USD Million)
 
Table 15.29 biOasis: Funding Instances (USD Million)
 
Table 15.30 Angiochem: Funding Instances (USD Million)
 
Table 15.31 Product Development and Commercialisation Agreements: Distribution by Focus of Technology
 
Table 15.32 Technology Licensing Agreements: Distribution by Focus of Technology
 
Table 15.33 Research Collaboration Agreements: Distribution by Focus of Technology
 
Table 15.34 Technology Evaluation Agreements: Distribution by Focus of Technology
 
Table 15.35 Product Licensing Agreements: Distribution by Focus of Technology
 
Table 15.36 Manufacturing and Supply Agreements: Distribution by Focus of Technology
 
Table 15.37 Clinical Trial Collaborations: Distribution by Focus of Technology
 
Table 15.38 Other Agreements: Distribution by Focus of Technology
 
Table 15.39 Delivery in Biotherapeutics: Year Wise Distribution of Partnership Instances
 
Table 15.40 Collaborations: Distribution by Type of Partnership
 
Table 15.41 Funding: Cumulative Number of Investments by Year, 1998-2015
 
Table 15.42 Funding Instances: Distrinutoi by Type of Funding, 1998-2015
 
Table 15.43 Funding Instances: Distribution by Total Amount Invested, 1998-2015
 
Table 15.44 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
 
Table 15.45 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
 
Table 15.46 Overall Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
 
Table 15.47 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
 
Table 15.48 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
 
Table 15.49 Overall Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
 
Table 15.50 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
 
Table 15.51 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
 
Table 15.52 Subcutaneous Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
 
Table 15.53 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
 
Table 15.54 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
 
Table 15.55 Subcutaneous Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
 
Table 15.56 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
 
Table 15.57 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
 
Table 15.58 Oral Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
 
Table 15.59 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
 
Table 15.60 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
 
Table 15.61 Oral Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
 
Table 15.62 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Conservative Scenario (USD Billion)
 
Table 15.63 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Base Scenario (USD Billion)
 
Table 15.64 Transdermal Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020): Optimistic Scenario (USD Billion)
 
Table 15.65 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
 
Table 15.66 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
 
Table 15.67 Transdermal Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
 
Table 15.68 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Conservative Scenario (USD Billion)
 
Table 15.69 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Base Scenario (USD Billion)
 
Table 15.70 Other Formulation and Drug Delivery Technologies Market, Short-Midterm (2015-2020), Optimistic Scenario (USD Billion)
 
Table 15.71 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Conservative Scenario (USD Billion)
 
Table 15.72 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Base Scenario (USD Billion)
 
Table 15.73 Other Formulation and Drug Delivery Technologies Market, Long term (2020-2025): Optimistic Scenario (USD Billion)
 
Table 15.74 Overall Biotherapeutics Formulation and Delivery Technologies Market: Comparative Evolution Scenarios, 2015, 2020 and 2025 (USD Billion)
 

 

Following companies have been mentioned in this report.

  1. 4P Therapeutics
  2. AbbVie
  3. ADOCIA
  4. Advanced Accelerator Applications
  5. Aegis Therapeutics
  6. Aerogen
  7. Affilogic
  8. Affinity Therapeutics
  9. Agila Specialities
  10. AIMM Therapeutics
  11. Albany Medical College
  12. Alchemia
  13. Alcyone
  14. Allergan
  15. Alrise Biosystems
  16. Althea
  17. Amarantus BioSciences
  18. AmatsiSEPS
  19. Angiochem
  20. Aphios
  21. Applied Molecular Transport
  22. Apricus Biosciences
  23. Aquarius Biotechnologies (Acquired by Matinas Biopharma)
  24. Aradigm
  25. Aratana Therapeutics
  26. Arecor
  27. ArmaGen
  28. Arsenal Medical
  29. Asahi Kasei Pharma
  30. Ascendis Pharma
  31. AstraZeneca
  32. Axela Biosensors
  33. Battelle
  34. Baxter
  35. Bayer Healthcare
  36. biOasis Technologies
  37. BioCardia
  38. Biodel
  39. BioLingus
  40. BrainsGate
  41. Caleva Process  Solutions
  42. Camarus AB
  43. CannScience Innovations
  44. Capsugel
  45. Carbylan Therapeutics
  46. Carlina Technologies
  47. CarThera
  48. Catalent Pharma
  49. CellProThera
  50. Chiasma Pharmaceuticals
  51. Circassia Pharmaceuticals
  52. Corium International
  53. Cosmo Pharmaceuticals
  54. CrossLink Bioscience
  55. Cubist Pharmaceuticals
  56. Dainippon Sumitomo
  57. Delpor
  58. DelSiTech
  59. DNAtrix
  60. DNX
  61. Dr. Reddy's
  62. Durect Corporation
  63. Dynamic Microbials
  64. Eisai
  65. Ekteino
  66. Elcam Medical
  67. Eli Lilly
  68. Emisphere
  69. Encap
  70. Endo International
  71. Entrega Bio
  72. ETI Karle Clinical
  73. ExcelseBio
  74. Extend Biotechnology
  75. Ferring Pharmaceuticals
  76. Flamel Technologies
  77. FluGen
  78. Galena Biopharma
  79. GALVmed
  80. GenBiotech
  81. Genentech
  82. Generex Biotechnology
  83. Generium
  84. Genta
  85. Genzyme
  86. Geron
  87. GlaxoSmithKline
  88. Graybug
  89. GSK
  90. H Lundbeck
  91. Halozyme Therapeutics
  92. Hikma Pharmaceuticals
  93. Hospira
  94. Hovione
  95. ICB International
  96. Innocore
  97. Intarcia Therapeutics
  98. Integrated Animal Health
  99. Intranasal Technology Inc (ITI)
  100. Intrexon
  101. Janssen Pharmaceuticals
  102. JCR Pharmaceuticals
  103. Johnson and Johnson
  104. JRX Biotechnology
  105. Kaer Therapeutics
  106. KemPharm
  107. Kereos
  108. Kurve Technology
  109. Kytogenics Pharmaceuticals
  110. Landec
  111. Laser Detect Systems
  112. Latitude Pharmaceuticals
  113. Lauren Sciences
  114. Le Métier de Beauté
  115. Leukocare Biotechnology
  116. Lipotek
  117. Liquidia Technologies/ Envisia Therapeutics
  118. Lung Rx
  119. Lysogene
  120. Medallion Therapeutics
  121. Medicure
  122. MedImmune
  123. MedinCell
  124. Medpace
  125. Merck
  126. Merrion Pharmaceuticals
  127. Midatech Group
  128. MIS Dental Implants Technologies
  129. Monosol Rx
  130. Mountain View Pharmaceuticals
  131. MSD Animal Health
  132. Mylan
  133. Nano Precision Medical
  134. Nanomerics
  135. NanoPass Technologies
  136. Nanovector
  137. NeuroNano
  138. Neurotech
  139. NHTherapeutics
  140. NOD Pharmaceuticals
  141. Novartis
  142. Novo Nordisk
  143. Oakwood Laboratories
  144. Octoplus
  145. Ocular Therapeutix
  146. Opsona Therapeutics
  147. Oramed Pharmaceuticals
  148. Orbis Biosciences
  149. Orion Pharma
  150. Pacira Pharmaceuticals
  151. Pantec Biosolutions
  152. PATH
  153. Patheon
  154. PCI Biotech
  155. Pearl Therapeutics
  156. Peptineo
  157. Permeon Biologics
  158. Pfizer
  159. Pharmidex
  160. PhaseBio Pharmaceuticals
  161. Phosphagenics
  162. Phylogica
  163. PolyPid
  164. ProCore Bio Med
  165. ProLynx
  166. Prometheon Pharma
  167. Protheragen
  168. Proxima Concepts
  169. pSivida
  170. Pulmatrix
  171. Rani Therapeutics
  172. Roche
  173. Ruthigen
  174. Sagetis Biotech
  175. Sanofi
  176. Sanofi Aventis
  177. Santen
  178. Scil Proteins
  179. Serina Therapeutics
  180. Servier
  181. Shire
  182. Smoofi
  183. Solvanix
  184. Stallergenes
  185. Sterigenics
  186. Strativa Pharmaceuticals
  187. Suda
  188. Swiss Caps AG
  189. Symphony Medical
  190. Synthelis
  191. Takeda Pharmaceuticals
  192. Tamarisk Technologies Group
  193. Targeted Cell Therapies
  194. TheraKine
  195. Tibotec
  196. Transdermal Corp.
  197. Transdermal Specialties
  198. UCB
  199. UCL
  200. Valerion Therapeutics
  201. Valeritas
  202. Vaxxas
  203. Vect-Horus
  204. Vectura
  205. Vestiq Pharmaceuticals
  206. Wacker Biotech
  207. Wyeth Pharmaceuticals
  208. Xenetic Biosciences
  209. Xenios AG
  210. Xeris Pharmaceuticals
  211. XL Protein GmbH
  212. XstalBio
  213. YEDA
  214. Zogenix
  215. Zosano Pharma

 

Following VC Firms have been mentioned in the report

  1. 5AM Ventures
  2. 7 Med Health Ventures
  3. Abingworth
  4. Advanced Technology Ventures
  5. Aegis Capital Corp
  6. AGF Private Equity
  7. Alpes Developpement Durable Investissement
  8. Alpha Associates
  9. Alta Partners
  10. Altitude Life Sciences Ventures
  11. AnGes MG
  12. Apax Partners
  13. Aphelion Capital
  14. ARCH Venture Partners
  15. Ascension Health Ventures
  16. Astellas Venture Management
  17. Atlas Venture
  18. Avida Group
  19. BDC Capital
  20. Beacon Angels
  21. Beta Fund
  22. Bill & Melinda Gates Foundation
  23. Bioam Gestion
  24. BioMed Ventures
  25. Boehringer Ingelheim Venture Fund
  26. Boston Harbor Angels
  27. Brandon Capital
  28. Broadfin Capital
  29. Burrill and Company
  30. Business Development Bank of Canada
  31. Canaan Partners
  32. Capital Royalty
  33. Capital Royalty Partners II
  34. CDC Enterprises
  35. Central Texas Angel Network
  36. Chase H&Q
  37. Cherrystone Angel Group
  38. Chicago Growth Partners
  39. CHL Medical Partners
  40. Clarus Ventures
  41. CNF Investments
  42. Covington Capital
  43. Crystal Horizon Investments
  44. Deerfield Management
  45. Deutsche Banc Alex. Brown
  46. DNA Biomedical Solutions Ltd.
  47. Domain Associates
  48. DSM Venturing
  49. Edward P. Bass group
  50. Essex Woodlands Health Ventures
  51. F2 Capital
  52. F2 Ventures
  53. F3 Ventures
  54. Firelake Capital Management
  55. Fletcher Spaght Ventures
  56. Fredric Price
  57. Glide Healthcare Partners
  58. Golden Seeds
  59. Google Ventures
  60. Granite State Angels
  61. Hambrecht & Quist
  62. Harbor Light Capital Partners
  63. Harkness & Hill
  64. Hatteras Venture Partners
  65. HBM BioVentures
  66. Health Ventures
  67. HealthCare Venture
  68. Hercules Technology Growth Capital
  69. HLM Venture Partners
  70. Hygea VCT Plc
  71. Idinvest Partners
  72. InCube Ventures
  73. InterSouth Partners
  74. InterWest Partners
  75. Investment Accelerator Fund-Life Sciences
  76. Israel HealthCare Ventures
  77. J&J Development Corporation
  78. Jerusalem Global Ventures
  79. Kaiser Permanante Ventures
  80. Kingsbridge Capital
  81. Ladenburg Thalmann & Co.
  82. LaunchPad Venture Group
  83. Life Science Angels
  84. LifeCare Partners
  85. Maryland Venture Fund
  86. Mass Medical Angels
  87. Maxim Group LLC
  88. Mayflower
  89. Medical Research Commercialisation Fund
  90. Merlin Biosciences
  91. MHR Funding Management
  92. Mitsui & Co. Global Investment
  93. Montaur Capital Partners
  94. Morningside Group
  95. MPM Capital
  96. New Enterprise Associates
  97. New Leaf Ventures
  98. New River Management V
  99. Nexus Medical Partners
  100. Nomura International
  101. Nomura Phase4 Ventures
  102. North Bridge Venture Partners
  103. North Country Angels
  104. Northland Securities
  105. Novartis Venture Fund
  106. Ofer Hi-Tech
  107. Omega Fund
  108. OneVentures
  109. ONSET Ventures
  110. OrbiMed Advisors
  111. OSI Pharmaceuticals
  112. Oxford Finance
  113. Oxford Finance Corporation
  114. Pacific Venture Opportunity Fund
  115. Pappas Ventures
  116. Pharmsynthez
  117. Pinemount Investment
  118. Pitango Venture Capital
  119. Polaris Partners
  120. Polaris Venture Partners
  121. Pound Capital
  122. ProQuest Investments
  123. Province of Nova Scotia
  124. Quantum Technology Partners
  125. RA Capital Management
  126. Rhône-Alpes Création
  127. Rock Springs Capital
  128. Rodman & Renshaw, Ladenburg Thalmann & Co.
  129. Savoy
  130. Scale Venture Partners
  131. SG Asset Management Private Equity
  132. Siemens Venture Capital
  133. Silicon Valley Bank
  134. Sofinnova Partners
  135. SofInnova Ventures
  136. Sparta LLC
  137. Sud Rhone-Alpes Capital
  138. SV Life Sciences
  139. Takeda Ventures
  140. Tech Coast Angels
  141. TechnoStart
  142. Texas Venture Labs
  143. The Halifax Group
  144. The Stevanato Group
  145. Think Equity Partners
  146. Thomas McNerney & Partners
  147. Vatera Healthcare Partners
  148. Venrock
  149. Venture Health
  150. Versant Ventures
  151. VG Partners
  152. Viaduct
  153. Viveris Management
  154. Vivo Capital
  155. Vivo Ventures
  156. Wakefield Group
  157. Warburg Dillon Read LLC, and Adams
  158. WBB Securities
  159. Welsh, Carson, Anderson & Stowe
  160. Western Life Sciences Venture Fund
  161. White Oak Global Advisors
  162. WR Hambrecht + Co
  163. Wuzhou Zhongheng Group
  164. Xenia Ventures
  165. Yissum Research Development

 

Following Institutes / Universities / Organisations have been mentioned in this report.

  1. National Institute of Diabetes and Digestive and Kidney Disease
  2. National Institute of Mental Health
  3. National Institute of Standards and Technology
  4. Bispebjerg University Hospital
  5. Brigham and Women’s Hospital
  6. Exeter University
  7. Infectious Disease Research Institute
  8. Laboratory for Drug Delivery (Georgia Institute of Technology)
  9. The School of  Pharmacy, University of London
  10. Technical University Munich (TUM)
  11. University of Cambridge

 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security